GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Supernus Pharmaceuticals Inc (NAS:SUPN) » Definitions » Median PS Value

Supernus Pharmaceuticals (Supernus Pharmaceuticals) Median PS Value : $49.78 (As of Apr. 25, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Supernus Pharmaceuticals Median PS Value?

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Supernus Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $10.738. Supernus Pharmaceuticals's 10-Year median PS Ratio is 4.6359. Therefore, the Median PS Value for today is $49.78.

As of today (2024-04-25), Supernus Pharmaceuticals's share price is $29.31. Supernus Pharmaceuticals's Median PS Value is $49.78. Therefore, Supernus Pharmaceuticals's Price to Median PS Value for today is 0.59.

The historical rank and industry rank for Supernus Pharmaceuticals's Median PS Value or its related term are showing as below:

SUPN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.43   Med: 0.58   Max: 0.61
Current: 0.59

During the past 13 years, the highest Price to Median PS Value of Supernus Pharmaceuticals was 0.61. The lowest was 0.43. And the median was 0.58.

SUPN's Price-to-Median-PS-Value is ranked better than
70.2% of 500 companies
in the Drug Manufacturers industry
Industry Median: 0.79 vs SUPN: 0.59

Supernus Pharmaceuticals Median PS Value Historical Data

The historical data trend for Supernus Pharmaceuticals's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Supernus Pharmaceuticals Median PS Value Chart

Supernus Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Median PS Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 67.65 61.28 49.78

Supernus Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Median PS Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 61.28 57.67 54.67 50.87 49.78

Competitive Comparison of Supernus Pharmaceuticals's Median PS Value

For the Drug Manufacturers - Specialty & Generic subindustry, Supernus Pharmaceuticals's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Supernus Pharmaceuticals's Price-to-Median-PS-Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Supernus Pharmaceuticals's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Supernus Pharmaceuticals's Price-to-Median-PS-Value falls into.



Supernus Pharmaceuticals Median PS Value Calculation

Supernus Pharmaceuticals's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=10.738*4.6359
=49.78

10-Year Median PS Ratio is 4.6359.
Supernus Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $10.738.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Supernus Pharmaceuticals  (NAS:SUPN) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Supernus Pharmaceuticals's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=29.31/49.78
=0.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Supernus Pharmaceuticals Median PS Value Related Terms

Thank you for viewing the detailed overview of Supernus Pharmaceuticals's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Supernus Pharmaceuticals (Supernus Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
9715 Key West Avenue, Rockville, MD, USA, 20850
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
Executives
Tami Tillotson Martin officer: Sr. V.P., Regulatory Affairs C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Newhall Charles W Iii director 1119 ST PAUL ST, BALTIMORE MD 21202
Frederick M. Hudson director 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Frank Mottola officer: Sr VP, Quality, GMP Oper. & IT 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Bethany Sensenig director C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615
Jack A. Khattar director, officer: President, CEO C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Padmanabh P. Bhatt officer: Sr. VP of IP, CSO C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Timothy C Dec officer: Senior Vice-President & CFO C/O OPGEN, INC., 708 QUINCE ORCHARD ROAD, SUITE 205, GAITHERSBURG MD 20878
Jonathan Rubin officer: SVP, Chief Medical Officer C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Schwabe Stefan K.f. officer: Executive Vice President R&D C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Gregory S Patrick officer: VP, Chief Financial Officer C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
James Patrick Kelly officer: Executive Vice-President & CFO C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Carrolee Barlow director C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Victor Vaughn officer: Sr. VP of Sales C/O SUPERNUS PHARMACEUTICALS, INC., 1550 EAST GUDE DRIVE, ROCKVILLE MD 20850
M James Barrett director, 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202